A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

311

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

NSCLCSolid Tumor

Interventions

DRUG

JAB-21822

JAB-21822 will be administered orally

DRUG

JAB-21822

JAB-21822 will be administered orally

DRUG

JAB-21822

JAB-21822 will be administered orally

Trial Locations (1)

Beijing Cancer Hospital, Beijing